AbbVie to present new analyses from pivotal phase 3 studies for upadacitinib in atopic dermatitis

Data are from Measure Up 1 & 2 studies submitted to FDA/EMA show significantly more patients on either dose of upadacitinib achieved at least EASI 90 vs. placebo at week 16 as well as significantly higher clinically meaningful itch reduction at week 4, maintained through week 16.

Source:

Biospace Inc.